Ranbaxy Buyers' $485M Deal In Generics MDL Gets Initial Nod

By Madeline Lyskawa (April 29, 2022, 6:04 PM EDT) -- Ranbaxy Pharmaceuticals drug purchasers nabbed initial approval of a $485 million global settlement struck in March over claims the drugmaker manipulated the U.S. Food and Drug Administration's generic-drug approval process to box out competitors.

U.S. District Court Judge Nathanial M. Gorton preliminary approved the two deals on Thursday in Massachusetts federal court and signed off on a proposed order laid out by the parties. Under the terms of the deals, $340 million is designated to direct purchasers and $145 million will go to end-payors such as health care plans.

In the multidistrict litigation, the end-payors asserted that Ranbaxy erroneously acquired exclusivity...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!